GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - AXSOME THERAPEUTICS INC

Financial Performance:

• Q3 revenue reached $260 million, exceeding a $1 billion annualized run rate for the first time.
• Net loss narrowed to $13 million; the company achieved quarterly cash-flow positivity for the first time, generating a $5–6 million profit when excluding $28 million in stock-based compensation.
• Avelity (Alzheimer's agitation and MDD) contributed $208 million in revenue, reflecting 53% year-over-year growth and a 15% sequential increase.
• Synosy generated $46 million in revenue, boosted by an $8.5 million milestone payment.
• Sembravo (migraine) grew to $3.9 million in quarterly revenue.
• The balance sheet holds $314 million in cash.
• Gross-to-Net (GTN) improved to the mid-to-high 40s in Q3, driven by expanded covered lives.

Guidance and Future Outlook:

• 2027 is projected to be a significant year with multiple potential milestones and catalysts across the pipeline.
• Avelity is expected to show continued robust growth in MDD and accelerated growth in the Alzheimer's agitation indication as new patient starts (NBRx) convert to refills.
• Long-term revenue growth is anticipated to accelerate through 2038–2039, supported by the pipeline and pediatric indications.
• 2027 Gross-to-Net is expected to mirror 2026 quarterly performance, with potential adjustments based on Medicare channel mix and coverage quality improvements.
• No specific quarterly revenue guidance was provided, but qualitative guidance remains focused on sustained robust growth.

Business Segments and Product Lines:

• Avelity: New Alzheimer's agitation indication saw New Prescription Volume (NBRx) increase 3.6x (from 1,000 to 3,600 monthly) post-approval; total weekly NBRx reached 3,800 in October. Sales force expanded from 270 to ~650 representatives in six months.
• Synosy: Continuing low-to-mid single-digit sequential growth on a fixed OPEX base; peak sales potential estimated at $300M–$500M.
• Sembravo: Strong clinical feedback and growing volume; focus is on navigating commercial dynamics.
• Pipeline: 10 programs, many at NDA or Phase 3. Upcoming catalysts include:
  • AXS-12 (Ripoxetine) for narcolepsy/cataplexy: PDUFA date set for May 1, 2025.
  • Binge Eating Disorder: Topline results expected Q1 2025; FDA requires two positive studies for NDA.
  • Synosy: ADHD pediatric studies ongoing; Shift Work Disorder study required for new indication; MDD randomized withdrawal trial enrollment expected next year.

Market and Competitive Landscape:

• Avelity coverage is strong with 89% total covered lives for MDD and 100% for Medicare (mostly no PA).
• Primary care penetration is currently ~25% with significant upside potential for both Avelity indications.
• Long-Term Care (LTC) channel activation is underway with a dedicated sales team; expected to drive growth through facility onboarding processes.
• AXS-12 is positioned as an orphan indication with a distinct mechanistic and tolerability profile compared to orexin inhibitors.
• Synosy competes in a market with rising placebo response rates; study designs account for this to detect signal.

Risks and Challenges:

• NBRx to TRx (refill) conversion lag: Growth in new prescriptions may take a few quarters to fully reflect in total revenue.
• Commercial disruption: Significant sales force expansion created transient operational challenges.
• FDA requirements: Binge Eating Disorder requires two adequate and well-controlled trials rather than relying on existing approval.
• Pricing pressure: Potential GTN fluctuations in 2027 dependent on mix shifts to Medicare and coverage quality optimization.
• Clinical trial execution: Ongoing trials face industry-wide challenges regarding elevated placebo response rates.

Management Commentary and Tone:

• Management expressed high confidence, stating "things have never been better" regarding the business trajectory.
• Tone emphasized robust growth, operational scalability, and a "luxury" of decision-making due to cash-flow positivity.
• The strategy of doubling the sales force rapidly was justified by strong payer access and a long product runway.
• Focus remains on top-line growth for current brands while maintaining a deep pipeline for future milestones.

Analyst Questions and Answers:

• Q: Avelity ADA growth trajectory? A: Driven by NBRx doubling from 1,000 to 3,600 monthly; TRx growth will lag but accelerate as the funnel fills. LTC expansion will contribute further.
• Q: Why the rapid sales force expansion? A: To capitalize on new indications and strong payer access immediately, accepting short-term disruption for long-term durable growth.
• Q: Net price trends in 2027? A: Expected to track 2026 quarterly trends; improvements in coverage quality could pressure GTN slightly.
• Q: Binge Eating Disorder path to NDA? A: Requires two positive studies; top-line expected Q1 2025.
• Q: Market view on AXS-12 vs. Orexin inhibitors? A: AXS-12 offers distinct efficacy/tolerability; leverage existing sleep infrastructure for minimal incremental investment.
• Q: Margin evolution post cash-flow positivity? A: Focus remains on top-line growth; sustained profitability will allow for strategic reinvestment in expansion.

Other Key Points:

• Avelity weekly NBRx growth trajectory: 2,400 (Q1) → 3,000 (Q2) → 3,550 (Q3) → 3,800 (October).
• Synosy has maintained a stable sales team of ~70 representatives for several years while growing.
• The company is currently "cash flow positive" but has not committed to sustained quarterly profitability without reinvestment.
• Pediatric expansion for Avelity is planned for the 2038–2039 timeframe.